Document:

<PAGE>

                                                                   EXHIBIT 10.61

            SECOND AMENDED AND RESTATED NAME AND LIKENESS AGREEMENT

     This SECOND AMENDED AND RESTATED NAME AND LIKENESS AGREEMENT (the
"Agreement") is made and entered as of June 22, 2000 by and among C. Everett
Koop, M.D. ("Koop") and drkoop.com, Inc., a Delaware corporation ("DKC" or the
"Company"), formerly Empower Health Corporation.

                                   RECITALS:

     A.  On January 5, 1999, Koop and DKC entered into a predecessor to this
Agreement for the purpose of conveying to DKC certain rights to use the name,
likeness and other attributes of Koop (the "January Agreement").

     B.  On August 30, 1999, Koop and DKC entered into an amendment and
restatement of the January Agreement which superceded such agreement in all
respects (the "August Agreement")

     C.  The parties, by entering into this Agreement, intend to supersede the
August Agreement in all respects and, from and after the date hereof, to have
this Agreement replace such August Agreement.

                                  AGREEMENT:

     NOW THEREFORE for and in consideration of the premises, and the mutual
covenants and promises herein set forth, the parties hereto hereby agree as
follows:

     1.  Term and Termination:  The term of this Agreement (the "Term") will
begin effective on the date hereof and will extend for an initial term of seven
years.  Unless otherwise terminated as provided for below, the Agreement will
automatically renew thereafter for consecutive five-year terms.  The Agreement
may be terminated by either party upon written notice given not more than 270
and not less than 180 days before the expiration of any such five year period.
This Agreement may also be terminated by either party in the event of a material
breach or default by the other party as specified in Section 6.  Provided
termination is not the result of (i) a material breach or default by DKC that is
not cured after written notice as provided in the immediately preceding
sentence, or (ii) a termination of this Agreement by operation of Section 16,
DKC shall have the right for five years following termination to use the Koop
Name (the "Rebranding Period").  During the Rebranding Period, the Company's
right to use the Koop Name shall be non-exclusive except that (i) such usage
shall be exclusive with respect to any products or services involving or related
to Internet-based health information, healthcare related software services and
products, or electronic commerce and (ii) the Koop Name may not be licensed or
otherwise conveyed to any Direct Competitor of DKC as identified on Attachment
B.  In the event that termination occurs as a result of a material breach or
default by DKC that is not cured after written notice as provided herein, all
rights to use the Koop Name (as defined below) shall cease on the 90th day after
such termination and if the Agreement is terminated pursuant to Section 16 no
Rebranding Period shall exist.
<PAGE>

     2.  Right To Use Services:  During the Term and subject to all other
provisions of this Agreement, Koop agrees that DKC shall have the right to use
the Koop name, image or likeness (hereinafter the "Koop Name") in connection
with the Company's Internet-based health information network, healthcare related
software services and products or electronic commerce (collectively the
"Products") in accordance with Section 5 below.

     3.  Fees and Payment:  For all rights and privileges and services rendered
or provided for hereunder by Koop, DKC has granted to Koop, pursuant to the
general terms of its current stock option plan, options to purchase 214,400
shares of the common stock of DKC for an exercise price of $17.88 per share (the
"August Options") and will make an additional one-time grant of options to
purchase 1,000 shares of the common stock of DKC for an exercise price of $1.50
per share (the "2000 Options").  The (a) August options will continue to vest on
the existing vesting schedule which commenced in August 1999 (i.e., become
exercisable) at a rate of 8,933.33 options per month (subject to adjust for
stock splits and similar matters) provided that at the end of each such month
this Agreement shall remain in full force and effect; provided, however, that
all such options shall vest and become exercisable at such time as this
Agreement shall be terminated due to the material breach of this Agreement by
DKC in accordance with the default provisions contained in Sections 1 and 6 and
(b) the 2000 Options shall be vested immediately upon execution hereof.  The
foregoing options have been approved by a compensation committee consisting
solely of non-employee directors, or by the full board of directors of DKC (with
Koop abstaining), for purposes of Rule 16b-3 under the Securities Exchange Act.
The parties acknowledge that the January Agreement provided for a continuing
royalty on DKC revenue and expressly acknowledge that the obligation of DKC to
pay, and the right of Koop to receive, any such royalty was terminated effective
July 1, 1999.

     4.  Competitive Protection:  Effective as of the date of this Agreement and
continuing throughout the Term, Koop agrees that Koop will not render services
in the form of advertising and/or publicizing of any items, products or services
which are directly competitive with DKC's Products including, without
limitation, products or services involving or related to any Internet-based
health information network, healthcare-related software services and products or
electronic commerce (hereinafter collectively the "Competitive Products") nor
will Koop permit or authorize the use of the Koop name and/or likeness
(photograph and/or drawing), voice, signature and/or endorsement directly or
indirectly, in connection with any such Competitive Products or by any Direct
Competitor as identified on Attachment B, except as may be used for the non-
profit, non-commercial activities of the Koop Institute provided such activities
are not related in any way to the promotion of any Competitive Products or any
Director Competitor.

     Without limiting the generality of the foregoing, Dr. Koop shall not
directly or indirectly participate in the development, production or promotion
of any Competitive Products or the products or services of any Direct Competitor
during the Term of this Agreement or any renewal term or during the Rebranding
Period, if any.

     5.  Right of Review:  The following elements of each Product shall be
subject to Koop's prior review and written approval, which approval shall not be
unreasonably withheld and shall be rendered within ten working days of receipt
of the element of the Product.  Koop

                                       2
<PAGE>

shall have the right to delegate his approval rights hereunder to a
Representative (as defined in Section 10 below) with the approval of DKC, such
approval not to be unreasonably withheld.

          (i)       Content and format, including manuscripts and other written
materials included with the Products, including drafts, and the final version.

          (ii)      Extent and content of all medical and technical information.

          (iii)     Professional medical consultants and advisors.

          (iv)      Title.

          (v)       Credit.

          (vi)      Means of advertising, promoting and selling the product,
including the Koop Name.

          (vii)     All advertising and promotional materials created, developed
or used in connection with the Products.

          (viii)    Any use of the Koop Name.

          (ix)      Any use not expressly contemplated by this Agreement.

     DKC and Koop shall work together to establish systems and procedures for
updating the Products based on advances in the field of medicine.

     6.  Default Provisions:

          (a) In the event that either party ("Defaulting Party")

             (i)    Materially defaults in the performance of any of its duties
or obligations set forth in this Agreement and such default is not substantially
cured within thirty (30) days after written notice is given by the other party
specifying the default; or

             (ii)   Defaults in the payment of any amount due to the other party
under this Agreement (if any) or in the case of DKC the performance of its
obligations under any stock option which default is not cured within thirty
(30) days after written notice is given by the other party specifying the
default; and

             (iii)  Provided, that upon a default under Section 6(i) and/or
(ii) by one party under this Agreement, the cure period for the next default by
such party shall be reduced (but not below ten days) by ten (10) days.

     Then the other party may, by giving written notice to such effect to the
Defaulting Party, terminate this Agreement as of the date specified in such
notice of termination.

                                       3
<PAGE>

         (b) Notwithstanding anything to the contrary herein contained, the
termination of the Agreement shall not relieve the parties of their obligations
existing at or prior to termination.

     7.  Obligations Limited to Payments:  The obligations to Koop hereunder
shall be fully performed and discharged as stipulated in Section 3, except for
those obligations that arise pursuant to the provisions for indemnifications
contained in Section 9.  It is understood that Koop is not an employee of DKC
and shall not be entitled to any rights or benefits granted to employees of DKC
by reason of the rendering hereunder of services by Koop.

     8.  Covenants Regarding Public Image:  DKC and Koop each covenants and
agrees that it will not knowingly permit, do or commit any act or thing that
would degrade, tarnish or deprecate or disparage the other party or the public
image of the other party in society or standing in the community, or prejudice
the other party, and that it will terminate such activities promptly upon
notice, it being understood that this Section 8 shall not apply to any dispute
involving this Agreement between Koop and DKC.

     9.  Indemnity:  DKC agrees to indemnify and hold harmless Koop, his
employees, assignees, and heirs against any and all claims, damages, liabilities
(including, but not limited to, liability for personal injury and liability for
breach of confidentiality), costs and expenses, including without limitation,
reasonable legal fees and costs arising out of the use of any material furnished
by DKC in connection with the services performed, or resulting from any patient
or third party action of any kind, or resulting in any way from the sale of
Products pursuant to this Agreement, or incurred for or by reason of the breach
of DKC of any of the obligations, warranties, agreements, covenants or
representations herein contained.  Koop shall provide prompt written notice of
any claim hereunder and DKC shall have the right to defend same.

     10. Incapacity or Death of Dr. Koop.  The rights granted to DKC herein are
intended to survive the incapacity or death of Dr. Koop.  Upon the occurrence of
any such event, all actions with respect to Koop hereunder, including without
limitation the approval rights provided in Section 5, shall be exercisable on
behalf of Koop by another person (the "Representative"), who, at the execution
date of this agreement, is hereby designated by Koop to be his son: Alan Koop,
and, in the event of Alan Koop's death, to be Koop's granddaughter:
Dr. Jennifer Koop.

     If prior to the death of Dr. Koop, he is pronounced to be incapacitated
(i.e., as being incapable of managing or conducting his own business affairs due
to physical or mental infirmity) by his Representative and Koop's son-in-law:
Gordon Thompson (such determination to be made only in association with a
physician chosen by and mutually acceptable to DKC and the Representative), then
said Representative shall thereafter and for so long as Koop is incapacitated
have full right to take any and all acts on behalf of Koop hereunder.

     Any Representative appointed in accordance with this Section 10 shall have
full right to take any and all acts on behalf of Koop hereunder and DKC may rely
on such acts as the lawful and duly authorized acts of Koop.

                                       4
<PAGE>

     11. Notices:  Any notice or other communication (including payment
hereunder) required or permitted to be given hereunder shall be in writing and
shall be hand delivered or sent next-day delivery by a company where a receipt
is given to the address as follows:

         To DKC:    drkoop.com, Inc.
                    Attention: President
                    7000 North Mopac
                    Suite 400
                    Austin, TX 78731

         To Koop:   C. Everett Koop, M.D.
                    Koop Institute at Dartmouth
                    College Street
                    Hanover, NH 03755

                              and

                    C. Everett Koop, M.D.
                    3 Ivy Pointe Way
                    Hanover, NH 03755

     Any such notice, direction or other instrument aforesaid, if delivered,
shall be deemed to have been given or made on the date on which it was delivered
or if sent next-day delivery shall be deemed to have been given or made on the
day following the day on which it was sent provided that any one of the parties
hereto may change its address by written notice to the other according to the
terms hereof and in such event this paragraph shall be deemed to be amended
accordingly.

     12. Informed Consent, Confidentiality and Security:  DKC represents and
warrants that when and if it introduces a program identified here as "Personal
Medical Records" that it will obtain appropriate and fully informed patient
consent to the receipt, retention, use and transfer of that patient's personal
or medical data and that such informed consent complies with all applicable
federal, state and local laws and regulations.  DKC further represents and
warrants that it shall take reasonable precautions to assure accuracy of and to
protect against negligent disclosure of and unauthorized access to all patients'
personal and medical data.

     13. Other Representations and Warranties:

     By DKC: DKC represents and warrants that:

         1.  It has the right to enter into this Agreement and that it is free
             to grant the rights granted herein.

         2.  The Products will not infringe the patent, copyright, trade
             secret, or property rights of any third party.

                                       5
<PAGE>

         3.  All aspects of the product, distribution and promotion of the
             Products shall comply in all material respects with all
             applicable laws and regulations.

         4.  It is not a party to any agreement that will be breached by or
             that prohibits it entering into or performing this Agreement.

     By Koop: Koop represents and warrants that:

         1.  He has the right to enter into this Agreement and that it is free
             to grant the rights granted herein.

         2.  He is not a party to any agreement that will be breached by or
             that prohibits it entering into or performing this Agreement.

         3.  DKC may apply for trademarks which incorporate the Dr. Koop name.

         4.  Koop has the right to enter into this Agreement and that he is
             free to grant the rights granted herein.

     14. Trademark Assignment and License:  DKC represents and warrants that it
has filed applications based on actual use with the United States Trademark
Office to register various marks, the status of which are as follows:

         (i)   DR. KOOP'S COMMUNITY: application filed with no pending number
assigned as of the execution of this Agreement; and

         (ii)  drkoop.com: application filed with no pending number assigned as
of the execution of this Agreement.

     All of the above, hereinafter the "Trademarks," are referenced for the good
and services described herein.  Upon termination of the Agreement and Rebranding
Period (if any), DKC shall assign its right, title and interest in the
Trademarks including the goodwill contained therein to Koop and any other marks
registered by DKC pursuant to this Agreement which include the word Koop.
Except as set forth herein, DKC acknowledges that it has no rights in the
Trademarks and that nothing contained in this Agreement or in any other document
shall vest any ownership rights in the Koop name.

     15. Miscellaneous:

         (a) Ownership and Publicity:  Except as granted herein, DKC does not
and may not claim any right, title or interest in or to Koop's name or likeness,
and acknowledges that all rights therein are and remain the property of Koop.

         (b) Insurance:  Prior to sale, promotion or distribution of any
Product other than reasonable, limited test marketing, DKC shall secure all
necessary and customary insurance, including a standard comprehensive general
liability insurance policy providing standard product liability protection,
directors and officers insurance and errors and omissions insurance listing

                                       6
<PAGE>

Koop as a named insured. Such insurance shall be in a form reasonably acceptable
to counsel for Koop and shall require the insurer to give Koop at least thirty
(30) days' prior written notice of any material modifications or cancellations.

         (c) Entire Agreement:  This Agreement constitutes the complete and
exclusive statement of the agreement between Koop and DKC with respect to the
subject matter herein set forth and supersedes all prior agreements by and
between the parties including, specifically, the January Agreement.

         (d) Amendments:  This Agreement may not be amended, altered or
terminated except in writing executed by or on behalf of each party.

         (e) Inurement:  This Agreement shall be binding upon the parties
hereto and their respective heirs, executors, administrators, legal
representatives, successors and permitted assigns.

         (f) Language:  The language used in this agreement shall be deemed to
be language chosen by the parties thereto to express their mutual intent and no
rule of strict construction against any party shall apply to any term or
condition thereof

         (g) Governing Law:  THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS.

         (h) Termination:  Upon any termination and except as provided for
herein, all rights to use Dr. Koop's name and likeness shall terminate.

         (i) Arbitration:  Any controversy or claim arising out of or relating
to this Agreement, or the breach thereof, shall be settled by binding
arbitration in accordance with the Commercial Rules of the American Arbitration
Association by a single arbitrator in a location to be agreed to by the parties,
and judgment upon the award rendered by the arbitrator may be entered in any
court having jurisdiction thereof and shall not be appealable.

         (j) Gender:  Wherever herein the singular number is used, the same
shall include the plural, and the masculine gender shall include the feminine
and neuter genders and vice versa, as the context may require.

         (k) Specific Performance.  The rights and obligations granted herein,
including without limitation the use of the name, likeness, personality and
other public attributes of Dr. C. Everett Koop, are extremely unique and
therefore the parties acknowledge that money damages will generally not be a
suitable remedy and therefore each agree that the rights and obligations granted
herein may be specifically enforced.

         (l) Counterparts:  This Agreement may be executed in counterparts,
each of which shall constitute an original but all of which taken together shall
constitute but one agreement.

                                       7
<PAGE>

         (m) Prior Version Superceded.  The prior version of the Second Amended
and Restated Name and Likeness Agreement, dated June 5, 2000, is expressly
superceded by this Agreement.

     16. Assignment and Change of Control:  Neither party may assign its rights
and obligations under this Agreement without the prior written consent of the
other.  In the event of a Specified Change of Control of DKC as hereinafter
defined, this Agreement shall terminate and all rights in the Koop Name granted
hereunder immediately revert to Koop and no Rebranding Period shall exist.  A
Specified Change of Control shall be defined as set forth in Attachment A.

                           (Signature Page Follows)

                                       8
<PAGE>

     IN WITNESS WHEREOF THIS AGREEMENT IS EXECUTED AS OF THE DATE FIRST WRITTEN
ABOVE.

                                            drkoop.com, Inc.

/s/ C. Everett Koop, M.D.                  /s/ Donald Hackett
---------------------------------           ---------------------------------
C. Everett Koop, M.D.                       Donald W. Hackett, President

                                       9
<PAGE>

                                 ATTACHMENT A

     For purposes of this Agreement "Change in Control" shall mean:

     (1) the acquisition by any individual, entity or group (a "Person"),
including any "person" within the meaning of Section 13(d)(3) or 14(d)(2) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), of beneficial
ownership within the meaning of rule 13d-3 promulgated under the Exchange Act,
of more than 50% of either (i) the then outstanding shares of common stock of
the Company (the "Outstanding Company Common Stock") or (ii) the combined voting
power of the then outstanding securities of the Company entitled to vote
generally in the election of directors (the "Outstanding Company Voting
Securities"); provided, however, that the following acquisitions shall not
constitute a Change in Control:  (A) any acquisition directly from the Company
(excluding any acquisition resulting from the exercise of a conversion or
exchange privilege in respect to outstanding convertible or exchangeable
securities), (B) any acquisition by the Company, (C) any acquisition by an
employee benefit plan (or related trust) sponsored or maintained by the Company
or any corporation controlled by the Company, (D) any acquisition by any
corporation pursuant to a reorganization, merger or consolidation involving the
Company, if, immediately after such reorganization, merger or consolidation,
each of the conditions described in clauses (i), (ii) and (iii) of section (3)
of this definition shall be satisfied;

     (2) individuals who, as of the date hereof, constitute the Board (the
"Incumbent Board") cease for any reason to constitute at least a majority of
such Board; provided, however, that any individual who becomes a director of the
Company subsequent to the date hereof whose election, or nomination for election
by the Company's stockholders, was approved by the vote of at least a majority
of the directors then comprising the Incumbent Board shall be deemed to have
been a member of the Incumbent Board;

     (3) approval by the stockholders of the Company of a reorganization, merger
or consolidation unless, in any such case, immediately after such
reorganization, merger or consolidation, more than 50% of the then outstanding
shares of common stock of the corporation resulting from such reorganization,
merger or consolidation and more than 50% of the combined voting power of the
then outstanding securities of such corporation entitled to vote generally in
the election of directors is then beneficially owned, directly or indirectly, by
all or substantially all of the individuals or entities who were the beneficial
owners, respectively, of the Outstanding Company Common Stock and the
Outstanding Company Voting Securities immediately prior to such reorganization,
merger or consolidation and in substantially the same proportions relative to
each other as their ownership, immediately prior to such reorganization, merger
or consolidation, of the Outstanding Company Common Stock and the Outstanding
Company Voting Securities, as the case may be; or

     (4) approval by the stockholders of the Company of (i) a plan of complete
liquidation or dissolution of the Company or (ii) the sale or the disposition of
all or substantially all of the assets of the Company other than to a
corporation with respect to which, immediately after such sale or other
disposition, more than 50% of the then outstanding shares of common stock
thereof

                                       10
<PAGE>

and more than 50% of the combined voting power of the then outstanding
securities thereof entitled to vote generally in the election of directors is
then beneficially owned, directly or indirectly, by all or substantially all of
the individuals and entities who were the beneficial owners, respectively, of
the Outstanding Company Common Stock and the Outstanding Company Voting
Securities immediately prior to such sale or other disposition and in
substantially the same proportions relative to each other as their ownership,
immediately prior to such sale or other disposition, of the Outstanding Company
Common Stock and the Outstanding Company Voting Securities, as the case may be.

     Notwithstanding anything to the contrary contained herein, a Specified
Change of Control shall only be deemed to have occurred if one of the
transactions in paragraphs (1) through (4) have occurred and:

          (a) the acquiring party, directly or indirectly, is related to,
controlled by, a party with substantial interests in the alcohol, tobacco or
firearms industry;

          (b) the acquiring party, directly or indirectly, is related to,
controlled by, or has a substantial interest in branches of the healing arts, in
the broadest sense, that would be deemed by organized, mainstream, orthodox
medicine as being unsafe, unethical or inappropriate; or

          (c) an arrangement of the sort described in (a) or (b) occurs
subsequent to such a Change in Control.

                                       11
<PAGE>

                                 ATTACHMENT B

     Direct Competitors shall include the following, which list shall be updated
from time to time upon delivery by DKC to Koop of parties that should be added
because they have become material competitors in the marketplace or deleted. Any
disagreement to such an update shall be resolved by arbitration in accordance
with Section 14(i).

1.   Accesshealth.com

2.   Ahn.com

3.   Betterhealth.com

4.   Healthcentral.com

5.   Healtheon/WebMD

6.   Healthgate.com

7.   Intelihealth.com

8.   Mayohealth.org

9.   Mediconsult.com

10.  Onhealth.com

11.  Thriveonline.com

12.  American Online

13.  Microsoft

14.  Yahoo!

15.  Excite@home

16.  Lycos Corporation

17.  Infoseek/The Walt Disney Company

18.  PlantRx

19.  Drugstore.com

20.  IMS Health, Inc.

21.  McKesson/HBOC

22.  Synoptics

                                       12<PAGE>

                                                                   EXHIBIT 10.62

                                DRKOOP.COM, INC.

                           PLACEMENT AGENCY AGREEMENT

Commonwealth Associates, L.P.
830 Third Avenue
New York, New York 10022
                                                                   June 23, 2000

Gentlemen:

     This Placement Agency Agreement (the "Agency Agreement") confirms the
retention by drkoop.com, Inc., a Delaware corporation (the "Company"), of
Commonwealth Associates, L.P., a New York limited partnership ("Commonwealth,"
or the "Placement Agent"), to act as the sales agent, on a best efforts basis,
in connection with the private placement of the Preferred Units (as defined
below) of the Company, on the terms set forth below.

     The Company proposes to offer for sale solely to "accredited investors," in
a private placement (the "Offering"), up to 150 units (the "Preferred Units") at
$100,000 per Preferred Unit, each Preferred Unit consisting of (i) 10,000 shares
(the "D Preferred Shares") of the Company's Series D 8% Convertible Preferred
Stock (the "Preferred Stock") having the rights and preferences set forth in a
Certificate of Designation of Series D Preferred Stock (the "Series D
Designation"), and (ii) seven-year warrants (the "Preferred Warrants") to
purchase a number of shares of Common Stock equal to 25% of the number of shares
of common stock, par value $0.001 per share ("Common Stock"), of the Company
issuable upon conversion of the D Preferred Shares (the "Warrant Shares"). A
minimum of 50 Preferred Units ($5,000,000) (the "Minimum Offering") and a
maximum of 150 Preferred Units ($15,000,000) (the "Maximum Offering") will be
sold in the Offering. The Maximum Offering may be increased by up to 50
Preferred Units ($5,000,000) at the option of the Placement Agent in the event
of over-subscription and then up to an additional 50 Preferred Units at the
option of the Company. The Preferred Units will be offered pursuant to those
terms and conditions mutually acceptable to the Placement Agent and the Company
as reflected in a Confidential Private Placement Memorandum prepared by the
Company in form and substance satisfactory to the Placement Agent and its
counsel (the "Offering Memorandum").  The Minimum Offering will be made on a
"best efforts - all-or-none" basis and the balance of the Offering will be made
on a "best efforts" basis.  The Preferred Units will be offered in accordance
with Regulation D promulgated by the Securities and Exchange Commission (the
"SEC").

     On the date hereof, Commonwealth has arranged for senior secured debt
financing in the amount of $1,500,000 for the Company (the "Bridge Financing")
in the form of senior secured bridge notes in the aggregate principal amount of
$1,500,000 (the "Bridge Notes") issued to Commonwealth and ComVest Venture
Partners, L.P.  The Bridge Financing shall be repaid out of the proceeds of the
Offering provided there is proceeds to the Company of at least $7,500,000.
<PAGE>

In consideration of the Bridge Financing, the Company has issued to Commonwealth
or its designees seven-year warrants (the "Bridge Warrants" and collectively
with the Bridge Notes, the "Bridge Securities") to purchase 4,000,000 shares of
Common Stock ("Bridge Shares"), at an exercise price of $0.75 per share. The
Company's obligation under the Bridge Notes is secured by certain assets of the
Company upon the terms and subject to the conditions specified in the related
general security agreement.

     The (i) Offering Memorandum, as it may be amended or supplemented from time
to time (including any documents incorporated therein by reference or
otherwise), (ii) the form of subscription agreement between the Company and each
subscriber for the Offering (the "Subscription Agreement"), and (iii) the
exhibits which are part of the Offering Memorandum and/or the Subscription
Agreement, are collectively referred to herein as the "Offering Documents."

     The Company will prepare and deliver to the Placement Agent a reasonable
number of copies of the Offering Documents in form and substance satisfactory to
the Placement Agent and its counsel.

     Each prospective investor subscribing to purchase Preferred Units
("Subscriber") will be required to deliver, among other things, a Subscription
Agreement and a confidential purchaser questionnaire ("Questionnaire") in the
form to be provided to offerees.  Capitalized terms used herein, unless
otherwise defined or unless the context otherwise indicates, shall have the same
meanings provided in the Offering Documents.

     1. Appointment of Placement Agent.

     (a) Commonwealth is hereby appointed exclusive placement agent of the
Company (subject to Commonwealth's right to have selected dealers ("Selected
Dealers") in good standing with the National Association of Securities Dealers
("NASD") participate in the Offering) during the offering periods for the
Offering herein specified for the purposes of assisting the Company in finding
qualified Subscribers in the Offering. The offering period for the Offering (the
"Preferred Offering Period") shall commence on the day the Offering Documents
relating thereto are first made available to Commonwealth by the Company for
delivery in connection with the offering for sale of the Preferred Units and
shall continue until the earlier to occur of: (i) the sale of the Maximum
Offering (plus the Preferred Units included in the Placement Agent's over-
allotment option); or (ii) July 31, 2000. In any event, however, the Placement
Agent shall use its best efforts to close at least $5,000,000 of gross proceeds
of the Offering by July 31, 2000. If the Minimum Offering is not sold prior to
the end of the Preferred Offering Period, the Offering will be terminated and
all funds received from Subscribers will be returned, without interest and
without any deduction. The day that the Preferred Offering Period terminates is
hereinafter referred to as the "Preferred Termination Date." The Preferred
Termination Date may be extended for up to thirty (30) days by mutual agreement
of the Placement Agent and the Company.

     (b) Subject to the performance by the Company in all material respects of
its obligations to be performed under this Agency Agreement and to the
completeness and accuracy of all representations and warranties of the Company
contained in this Agency Agreement, the

                                       2
<PAGE>

Placement Agent hereby accepts such agency and agrees to use its best efforts to
assist the Company in finding qualified Subscribers. It is understood that the
Placement Agent has no commitment to sell the Preferred Units. Commonwealth's
agency hereunder is not terminable by the Company except upon termination of the
Preferred Offering Period or a material breach by Commonwealth of its
obligations hereunder.

     (c) Subscriptions for Preferred Units shall be evidenced by the execution
by Subscribers of a Subscription Agreement. No Subscription Agreement shall be
effective unless and until it is accepted by the Company. The Placement Agent
shall not have any obligation to independently verify the accuracy or
completeness of any information contained in any Subscription Agreement or the
authenticity, sufficiency, or validity of any check delivered by any prospective
investor in payment for Preferred Units.

     (d) The Placement Agent and/or its affiliates may be investors in the
Offering.

     2. Representations and Warranties of the Company. The Company represents
and warrants to the Placement Agent and each Selected Dealer, if any, as
follows:

     (a) Securities Law Compliance. The offer, offer for sale, and sale of the
Preferred Units has not been registered with the SEC. The Preferred Units are to
be offered, offered for sale and sold in reliance upon the exemptions from the
registration requirements of Section 5 of the 1933 Act. The Company will use its
best efforts to conduct the Offering in compliance with the requirements of
Regulation D of the General Rules and Regulations under the 1933 Act, and the
Company will file all appropriate notices of offering with the SEC. The Company
has prepared the Offering Documents. During the term of the Offering, the
applicable Offering Documents will not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the
statements therein, in light of the circumstances in which they were made, not
misleading. If at any time prior to the completion of the Offering or other
termination of this Agency Agreement any event shall occur as a result of which
it becomes necessary to amend or supplement the Offering Documents relating
thereto so that they do not include any untrue statement of any material fact or
omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances then existing, not misleading, the
Company will promptly notify the Placement Agent and will supply the Placement
Agent with amendments or supplements correcting such statement or omission. The
Company will also provide the Placement Agent for delivery to all offerees and
purchasers and their representatives, if any, any information, documents and
instruments which the Placement Agent deems reasonably necessary to comply with
applicable state and federal law.

     (b) Organization. The Company and its "Subsidiaries" (which for purposes of
this Agency Agreement means any entity (i) in which the Company, directly or
indirectly, owns 51% of the capital stock or holds an equity or similar interest
and (ii) which conducts substantive business activities or holds material
assets) are corporations duly organized and validly existing in good standing
under the laws of the jurisdiction in which they are incorporated, and have the
requisite corporate power and authority to own their properties and to carry on
their business as now being conducted and as described in the Offering
Documents, to execute and deliver this Agency Agreement and to carry out the
transactions contemplated hereby (if a party hereto). Each of the Company and
its Subsidiaries is duly qualified as a foreign corporation to do

                                       3
<PAGE>

business and is in good standing in every jurisdiction in which its ownership of
property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in
good standing would not reasonably be expected to have a Material Adverse
Effect. As used in this Agency Agreement, "Material Adverse Effect" means any
material adverse effect on the business, properties, assets, operations, results
of operations or financial condition of the Company and its Subsidiaries, taken
as a whole, or on the transactions contemplated hereby or by the Transaction
Documents (as defined below in Section 3(b)(v)(B)). A complete list of all
Subsidiaries of the Company with substantive business activities is set forth in
Schedule 2(b) hereto.

     (c) Capitalization. The authorized, issued and outstanding capital stock of
the Company prior to the consummation of the transactions contemplated hereby is
set forth in Schedule 2(c). All of such outstanding shares have been and are, or
upon issuance will be, validly issued, fully paid and non-assessable. Except as
disclosed in Schedule 2(c), (i) no shares of the Company's capital stock are
subject to preemptive rights under Delaware law or any other similar rights or
any liens or encumbrances suffered or permitted by the Company; (ii) there are
no outstanding debt securities issued by the Company; (iii) there are no
outstanding options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights
convertible into, any shares of capital stock of the Company or any of its
Subsidiaries, or contracts, commitments, understandings or arrangements by which
the Company or any of its Subsidiaries is or may become bound to issue
additional shares of capital stock of the Company or any of its Subsidiaries or
options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, any
shares of capital stock of the Company or any of its Subsidiaries; (iv) there
are no agreements or arrangements under which the Company or any of its
Subsidiaries is obligated to register the sale of any of their securities under
the 1933 Act; (v) there are no outstanding securities of the Company or any of
its Subsidiaries which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the
Company or any of its Subsidiaries is or may become bound to redeem a security
of the Company or any of its Subsidiaries; (vi) there are no securities or
instruments containing anti-dilution or similar provisions that will be
triggered by the issuance of the Securities as described in this Agency
Agreement; and (vii) the Company does not have any stock appreciation rights or
"phantom stock" plans or agreements or any similar plan or agreement. All prior
sales of securities of the Company were either registered under the 1933 Act and
applicable state securities laws or exempt from such registration, and no
security holder has any rescission rights with respect thereto except to the
extent any such rights would not reasonably be expected to have a Material
Adverse Effect.

     (d) SEC Documents; Financial Statements. Since December 31, 1999, the
Company has filed all reports, schedules, forms, statements and other documents
required to be filed by it with the SEC pursuant to the reporting requirements
of the Securities Exchange act of 1934, as amended (the "1934 Act"), (all of the
foregoing filed after December 31, 1999 and prior to the date hereof and all
exhibits included therein and financial statements and schedules thereto and
documents incorporated by reference therein being hereinafter referred to as the
"SEC Documents"). As of their respective dates, the SEC Documents complied in
all material respects with the requirements of the 1934 Act and the rules and
regulations of the SEC promulgated

                                       4
<PAGE>

thereunder applicable to the SEC Documents. None of the SEC Documents, at the
time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. As of their respective dates, the
financial statements of the Company included in the SEC Documents complied as to
form in all material respects with applicable accounting requirements of the SEC
with respect thereto. Such financial statements have been prepared in accordance
with generally accepted accounting principles, consistently applied ("GAAP"),
during the periods involved (except (i) as may be otherwise indicated in such
financial statements or the notes thereto, or (ii) in the case of unaudited
interim statements, to the extent they may exclude footnotes or may be condensed
or summary statements), show all material liabilities, absolute or contingent,
of the Company required to be required to be recorded thereon, and fairly
present in all material respects the financial position of the Company as of the
dates thereof and the results of its operations and cash flows for the periods
indicated (subject, in the case of unaudited statements, to normal year-end
audit adjustments). As of the date hereof, the Company meets the requirements
for the use of Form S-3 for registration of the resale of the Common Stock
issuable upon exercise of the Preferred Warrants and upon conversion of the
Series D Preferred Stock.

     (e) Absence of Changes. Since December 31, 1999, there have been no
material adverse changes in the financial condition, business, properties or
prospects of the Company or of the Company and its Subsidiaries, taken as a
whole, other than changes referred to in the SEC Documents or in Schedule 2(e).
Except as described in the SEC Documents or in Schedule 2(e), since December 31,
1999, the Company has not incurred any liabilities or obligations, direct or
contingent, not in the ordinary course of business, or entered into any
transaction not in the ordinary course of business, which is material to the
business of the Company, and, except as set forth in Schedule 2(e), there has
not been any change in the capital stock of, or any incurrence of long-term debt
by, the Company, or any issuance of options, warrants or other rights to
purchase the capital stock of the Company, or any adverse change or any
development involving, so far as the Company can now reasonably foresee, a
prospective adverse change in the condition (financial or otherwise), net worth,
results of operations, business, key personnel or properties which would be
material to the business or financial condition of the Company, and the Company
has not become a party to, and neither the business nor the property of the
Company has become the subject of, any material litigation whether or not in the
ordinary course of business.

     (f) Title. Except as set forth in or contemplated by Schedule 2(f), the
Company has good and marketable title to all material properties and assets
owned by it, free and clear of all liens, charges, encumbrances or restrictions,
except as not prohibited by Section 4(B)(vii) of the Bridge Notes or such as are
not significant or important in relation to the Company's business; all of the
material leases and subleases under which the Company is the lessor or sublessor
of properties or assets or under which the Company holds properties or assets as
lessee or sublessee are in full force and effect, and the Company is not in
default in any material respect with respect to any of the terms or provisions
of any of such leases or subleases, and no material claim has been asserted by
anyone adverse to rights of the Company as lessor, sublessor, lessee or
sublessee under any of the leases or subleases mentioned above, or affecting or
questioning the right of the Company to continued possession of the leased or
subleased premises or assets

                                       5
<PAGE>

under any such lease or sublease. The Company owns, leases or licenses all such
properties as are necessary to its operations as described in the Offering
Documents.

     (g) Intellectual Property Rights. The Company and its Subsidiaries own or
possess adequate rights or licenses to use all trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights,
copyrights, inventions, licenses, approvals, governmental authorizations, trade
secrets and rights necessary to conduct their respective businesses as now
conducted. Except as set forth on Schedule 2(g), none of the Company's
trademarks, trade names, service marks, service mark registrations, service
names, patents, patent rights, copyrights, inventions, licenses, approvals,
government authorizations, trade secrets or other intellectual property rights
have expired or terminated, or are expected to expire or terminate within two
years from the date of this Agency Agreement, except where such expiration or
termination would not have either individually or in the aggregate a Material
Adverse Effect. The Company and its Subsidiaries do not have any knowledge of
any infringement by the Company or its Subsidiaries of trademarks, trade name
rights, patents, patent rights, copyrights, inventions, licenses, service names,
service marks, service mark registrations, trade secrets or other similar rights
of others, or of any such development of similar or identical trade secrets or
technical information by others and, except as set forth on Schedule 2(g), no
claim, action or proceeding has been made or brought against, or to the
Company's knowledge, has been threatened against, the Company or its
Subsidiaries regarding trademarks, trade name rights, patents, patent rights,
inventions, copyrights, licenses, service names, service marks, service mark
registrations, trade secrets or other infringement, except where such
infringement, claim, action or proceeding would not reasonably be expected to
have either individually or in the aggregate a Material Adverse Effect. Except
as set forth on Schedule 2(g), the Company and its Subsidiaries are unaware of
any facts or circumstances which might give rise to any of the foregoing. The
Company and its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties
except where the failure to do so would not have either individually or in the
aggregate a Material Adverse Effect.

     (h) Litigation. Except as set forth in or contemplated by Schedule 2(h),
there is no material action, suit, investigation, customer complaint, claim or
proceeding at law or in equity by or before any court, arbitrator, governmental
instrumentality or authority or other agency now pending or, to the knowledge of
the Company, threatened against the Company, the adverse outcome of which would
be reasonably likely to have a Material Adverse Effect. The Company is not
subject to any judgment, order, writ, injunction or decree of any Federal,
state, municipal or other governmental department, commission, board, bureau,
agency or instrumentality, domestic or foreign which have a Material Adverse
Effect.

     (i) Non-Defaults; Non-Contravention; Etc. Except as disclosed in Schedule
2(i), neither the execution, delivery and performance of this Agency Agreement
nor the consummation by the Company of the transactions contemplated hereby will
(i) result in a violation of its certificate of incorporation or any certificate
amendment thereto (collectively, "Certificate of Incorporation") or its by-laws
("By-laws"); (ii) conflict with, or constitute a default (or an event which with
notice or lapse of time or both would become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any
agreement, indenture or instrument to which the Company or any of its
Subsidiaries is a party; or

                                       6
<PAGE>

(iii) result in a violation of any law, rule, regulation, order, judgment or
decree (including federal and state securities laws and regulations and the
rules and regulations of the Nasdaq National Market on which the Common Stock is
traded or listed) applicable to the Company or any of its Subsidiaries or by
which any property or asset of the Company or any of its Subsidiaries is bound
or affected, except, in the cases of foregoing clauses (ii) and (iii), any
conflict, default or violation which would not reasonably be expected to result
in a Material Adverse Effect. Except as disclosed in Schedule 2(i), neither the
Company nor its Subsidiaries is in violation of any term of (i) its Certificate
of Incorporation, or its By-laws or their organizational charter or by-laws,
respectively, or (ii) any statute, rule or regulation applicable to the Company
or its Subsidiaries and neither the Company nor its Subsidiaries is in default
under any contract, agreement, mortgage, indebtedness, indenture, instrument,
judgment, decree or order, except for such violations or defaults which would
not, individually or in the aggregate, have a Material Adverse Effect. Except as
specifically contemplated by this Agency Agreement and except such as have been
obtained as of the date hereof, the Company is not required to obtain any
consent, authorization or order of, or make any filing or registration with, any
court or governmental agency or any regulatory or self-regulatory agency in
order for it to execute, deliver or perform any of its obligations under or
contemplated by this Agency Agreement or the Offering Documents in accordance
with the terms hereof or thereof. Except as disclosed on Schedule 2(i), the
Company is not in violation of the listing requirements of the Nasdaq National
Market as in effect on the date hereof and has no actual knowledge of any facts
which would reasonably lead to delisting or suspension of the Common Stock by
the Nasdaq National Market in the foreseeable future.

     (j) Taxes. Except as set forth in or contemplated by Schedule 2(j), the
Company has filed all Federal, state, local and foreign tax returns which are
required to be filed by it or otherwise met its disclosure obligations to the
relevant agencies and all such returns are true and correct in all material
respects. The Company has paid or adequately provided for all tax liabilities of
the Company as reflected on such returns or determined to be due on such returns
or pursuant to any assessments received by it or which it is obligated to
withhold from amounts owing to any employee, creditor or third party. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company know of no basis for any
such claim. The Company has properly accrued all taxes required to be accrued by
GAAP consistently applied. The tax returns of the Company have never been
audited by any state, or Federal authorities. The Company has not waived any
statute of limitations with respect to taxes or agreed to any extension of time
with respect to any tax assessment or deficiency.

     (k) Compliance With Laws; Licenses; Etc. The business of the Company and
its Subsidiaries is not being conducted in violation of any law, ordinance or
regulation of any governmental entity except for such violations the sanctions
for which either individually or in the aggregate would not reasonably be
expected to have a Material Adverse Effect, and the Company has not received
notice of any violation of or noncompliance with any Federal, state, local or
foreign, laws, ordinances, regulations and orders applicable to its business
which has not been cured, the violation of, or noncompliance with which, would
be reasonably likely to have a Material Adverse Effect. The Company has all
material licenses and permits and other governmental certificates,
authorizations and permits and approvals (collectively, "Licenses")

                                       7
<PAGE>

required by every Federal, state and local government or regulatory body for the
operation of its business as currently conducted and the use of its properties,
except where the failure to be licensed or possess a permit would not reasonably
be expected to have a Material Adverse Effect. The Licenses are in full force
and effect and to the Company's knowledge no violations currently exist in
respect of any License and no proceeding is pending or threatened to revoke or
limit any thereof.

     (l) Authorization of Agency Agreement; Enforceability; Etc. The Company has
the requisite corporate power and authority to enter into and perform its
obligations under this Agency Agreement and the Subscription Agreement, and the
Fund Escrow Agreement (as defined below). The execution and delivery of this
Agency Agreement and the Funds Escrow Agreement by the Company and the
consummation by it of the transactions contemplated hereby and thereby, have
been duly authorized by the board of directors of the Company ("Board of
Directors") and no further consent or authorization is required by the Company,
its Board of Directors or its stockholders except the approval of the issuance
of the D Preferred Shares and Preferred Warrants in the Offering by stockholders
of the Company required by the rules of the Nasdaq National Market or receipt of
a waiver therefrom. This Agency Agreement has been duly executed and delivered
by the Company and constitutes the valid and binding obligations of the Company
enforceable against the Company in accordance with its terms, except as such
enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally, the enforcement of creditors' rights and
remedies.

     (m) Authorization of D Preferred Shares, Preferred Warrants Etc. Except as
set forth in or contemplated by Schedule 2(m), the issuance, sale and delivery
of the D Preferred Shares and the Preferred Warrants have been duly authorized
by all requisite corporate action of the Company. When so issued, sold and
delivered in accordance with this Agreement and the Offering Documents for the
consideration set forth therein, the D Preferred Shares and the Preferred
Warrants will be duly executed, issued and delivered and will constitute valid
and legal obligations of the Company enforceable in accordance with their
respective terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the
enforcement of creditors' rights and remedies, and, in each case, will not be
subject to preemptive or any other similar rights of the stockholders of the
Company.

     (n) Authorization of Reserved Shares. Except as set forth in or
contemplated by Schedule 2(n), the issuance, sale and delivery by the Company of
the shares of Common Stock issuable upon conversion or exercise of the D
Preferred Shares and the Preferred Warrants (the "Reserved Shares") have been
duly authorized by all requisite corporate action of the Company, and the
Reserved Shares have been duly reserved for issuance upon conversion or exercise
of all or any of the D Preferred Shares or Preferred Warrants, except to the
extent the number of shares of Common Stock issuable upon conversion or exercise
of the D Preferred Shares, the Preferred Warrants, the Bridge Warrants or the
Agency Warrants exceed the number of authorized shares of Common Stock in the
Company's Certificate of Incorporation as a result of the respective conversion
price and exercise price reset terms of the D Preferred Shares, the Preferred
Warrants, the Bridge Warrants or the Agency Warrants in which case the Company
shall use reasonable

                                       8
<PAGE>

best efforts to seek stockholder approval of and file a certificate of amendment
with respect to its Certificate of Incorporation to increase the numbers of
authorized shares of Common Stock so that the Company may legally issue the
shares of Common Stock issuable upon conversion or exercise of the D Preferred
Shares, the Preferred Warrants the Bridge Warrants or the Agency Warrants
following the foregoing adjustment to the respective conversion price or
exercise price. When so issued, sold, paid for and delivered for the
consideration set forth in the Offering Documents, the Reserved Shares will be
validly issued and outstanding, fully paid and nonassessable, and not subject to
preemptive rights under Delaware law or any other similar rights of the
stockholders of the Company or others.

     (o) Exemption from Registration. Assuming (i) the accuracy of the
information provided by the respective Subscribers in the Subscription Agreement
and Questionnaire and the Purchasers in the Subscription Agreement (ii) that all
of the offerees and Subscribers are "accredited investors" as such term is
defined in Rule 501 of Regulation D and (iii) that the Placement Agent has not
engaged, nor will engage, in connection with the Offering, in any form of
general solicitation or general advertising within the meaning of Rule 502(c) of
Regulation D, the offer and sale of the Preferred Units and the Preferred
Warrants pursuant to the terms of this Agency Agreement are exempt from the
registration requirements of the 1933 Act and the rules and regulations
promulgated thereunder. The Company is not disqualified from the exemption under
Regulation D by virtue of the disqualification contained in Rule 507 thereof.

     (p) Registration Rights. Except with respect to holders of the Preferred
Units and the Preferred Warrants, and except as set forth in Schedule 2(p), no
person has any right to cause the Company to effect the registration under the
1933 Act of any securities of the Company. The Company shall grant registration
rights under the 1933 Act to the Subscribers and/or their transferees as more
fully described in the applicable Subscription Agreements.

     (q) Brokers. Neither the Company nor any of its officers, directors,
employees or stockholders has employed any broker or finder in connection with
the transactions contemplated by this Agency Agreement other than the Placement
Agent.

     (r) Title to Securities. When certificates representing the D Preferred
Shares and the Preferred Warrants have been duly delivered to the Subscribers in
the Offering, and payment shall have been made therefor, such persons shall
receive from the Company good and marketable title to such securities free and
clear of all liens, encumbrances and claims whatsoever (with the exception of
claims arising through the acts or omissions of the purchasers and except as
arising from applicable Federal and state securities laws), and the Company
shall have paid all taxes, if any, in respect of the original issuance thereof
in the United States.

     (s) Right of First Refusal. No person, firm or other business entity is a
party to any agreement, contract or understanding, written or oral entitling
such party to a right of first refusal with respect to offerings by the Company.

3.  Closing and Fees.

     (a) Closing of the Offering. Provided the Minimum Offering shall have been
subscribed for and funds representing the sale thereof shall have cleared, a
closing (the "Initial

                                       9
<PAGE>

Preferred Closing") shall take place at the offices of the Placement Agent, 830
Third Avenue, New York, New York within three business days thereafter (but in
no event later than five days following the Preferred Termination Date), which
closing date may be accelerated or adjourned by agreement between the Company
and the Placement Agent. At the Initial Preferred Closing, payment for the
Preferred Units issued and sold by the Company shall be made against delivery of
the D Preferred Shares and Preferred Warrants comprising such Preferred Units.
In addition, subsequent closings of the Offering (if applicable) may be
scheduled at the discretion of the Company and the Placement Agent, each of
which shall be deemed a "Preferred Closing" hereunder. The date of the last
closing of the Offering is hereinafter referred to as the "Final Closing" and
the date of any Preferred Closing hereunder is hereinafter referred to as a
"Closing Date".

     (b) Conditions to Placement Agent's Obligations. The obligations of the
Placement Agent hereunder will be subject to the accuracy in all material
respects of the representations and warranties of the Company herein contained
as of the date hereof and as of each Closing Date of the Placements, to the
performance by the Company of its obligations hereunder and to the following
additional conditions:

        (i) Due Qualification or Exemption. (A) The Offering will become
     qualified or be exempt from qualification under the securities or "blue
     sky" laws of the several states pursuant to paragraph 4(d) below not later
     than the Initial Preferred Closing Date, and (B) at any Closing Date no
     stop order suspending the sale of the Preferred Units and Bridge Securities
     shall have been issued, and no proceeding for that purpose shall have been
     initiated or threatened;

        (ii) No Material Misstatements. Neither the blue sky qualification
     materials nor the Offering Documents, nor any supplement thereto, will
     contain any untrue statement of a fact which in the reasonable opinion of
     the Placement Agent is material, or omits to state a fact, which in the
     reasonable opinion of the Placement Agent is material and is required to be
     stated therein, or is necessary to make the statements therein, in light of
     the circumstances under which they were made, not misleading;

        (iii) Compliance with Agreements. The Company will have complied in all
     material respects with all agreements and satisfied all conditions on its
     part to be performed or satisfied hereunder at or prior to each Preferred
     Closing;

        (iv) Corporate Action. The Company has or will have taken all necessary
     corporate action, including, without limitation, obtaining the approval of
     its Board of Directors and stockholders, for the execution and delivery of
     this Agency Agreement, the performance by the Company of its obligations
     hereunder and the Offering contemplated hereby (including the approval of
     the issuance of the D Preferred Shares and Preferred Warrants in the
     Offering by the Company's stockholders required by the rules of the Nasdaq
     National Market unless a waiver therefrom has been obtained provided that,
     if the terms of such waiver require stockholder ratification of the
     issuance, the Placement Agent shall receive an irrevocable proxy from each
     of the executive officers and directors solely for the purpose of voting in
     favor of such ratification);

                                       10
<PAGE>

        (v) Opinion of Company Counsel. At each Preferred Closing, the Placement
     Agent shall receive the opinion of counsel to the Company, substantially to
     the effect that:

                (A) the Company is a corporation duly incorporated, validly
     existing and in good standing under the laws of the Delaware, has all
     requisite corporate power and authority necessary to own or hold its
     respective properties and conduct its business in the manner described in
     the Offering Memorandum, and is duly qualified or licensed to do business
     and is in good standing as a foreign corporation in each jurisdiction
     listed on an exhibit to such opinion;

                (B) the Company has all requisite corporate power and authority
     to execute and deliver and perform its obligations at closing under this
     Agency Agreement, the Subscription Agreements, the Preferred Warrants (and
     each of the other documents to be entered into by the Company in connection
     therewith, including, but not limited to the Agency Warrants and the
     Registration Rights Agreement) (collectively, the "Transaction Documents"),
     and to consummate the transactions contemplated hereby and thereby;

                (C) each of this Agency Agreement and the other Transaction
     Documents has been duly and validly authorized, executed and delivered by
     the Company, and is the valid and binding obligation of the Company,
     enforceable against it in accordance with its terms, subject to customary
     exceptions;

                (D) to such counsel's knowledge and without independent
     investigation, there are no outstanding warrants, options, agreements,
     convertible securities, preemptive rights or other commitments pursuant to
     which the Company is, or may become, obligated to issue any shares of its
     capital stock or other securities of the Company other than as set forth in
     Schedule 2(c);

                (E) assuming (i) the accuracy of the information provided by the
     Subscribers in the Subscription Agreements; (ii) the accuracy of the
     information provided by the purchasers in the Agreement; and (iii) that the
     Placement Agent has not engaged, nor will engage, in connection with the
     Offering, in any form of general solicitation or general advertising within
     the meaning of 502(c) of Regulation D, the issuance and sale of the
     Preferred Units are exempt from the registration requirements set forth in
     Section 5 of the 1933 Act;

                (F) the Preferred Units, Agency Warrants, the Bridge Securities
     and the Common Stock conform as to legal matters in all material respects
     to the statements relating thereto contained in the Offering Memorandum.
     (i) The shares of Series D Preferred Stock included in the Preferred Units,
     when issued, delivered to and paid for by the Subscribers therefor pursuant
     to the terms of this Agency Agreement and the Subscription Agreements, (ii)
     the Warrant Shares, when issued to, delivered to and paid for pursuant to
     the terms of the Preferred Warrants and the Agency Warrants, upon payment
     therefor, and (iii) the shares of Common Stock issuable upon conversion of
     the Series D Preferred Stock, shall be duly authorized, validly issued,
     fully paid, and

                                       11
<PAGE>

     nonassessable, and shall not have been issued in violation of any
     preemptive rights under Delaware law (assuming no adjustments pursuant to
     anti-dilution provisions);

                (G) no consent, authorization, approval, order, license,
     certificate, or permit of or from, or declaration or filing with, any
     federal governmental authority is required by the Company for the
     execution, delivery, or performance by the Company of this Agency Agreement
     and the other Transaction Documents, and the consummation of the
     transactions contemplated hereby and thereby, except the filing of a Notice
     of Sales of Securities on Form D pursuant to Regulation D and such
     consents, authorizations, approvals, registrations, and qualifications as
     may be required under blue sky laws in connection with the issuance, sale,
     and delivery of the Preferred Units pursuant to this Agency Agreement. No
     consent of any party to any material contract, agreement, instrument,
     lease, license, arrangement, or understanding identified to counsel as
     such, is required for the execution, delivery, or performance of this
     Agency Agreement or the other Transaction Documents, or the consummation of
     the transactions contemplated hereby or thereby; and the execution,
     delivery and performance of this Agency Agreement and the other Transaction
     Documents, and the consummation of the transactions contemplated hereby and
     thereby, will not violate, result in a breach of, conflict with, or (with
     or without the giving of notice or the passage of time or both) entitle any
     party to terminate or call a default under any such material contract,
     agreement, instrument, lease, license, arrangement, or understanding
     identified to counsel as such, or violate or result in a breach of any term
     of the certificate of incorporation or by-laws of the Company, or violate,
     result in a breach of, or conflict with any law, rule or regulation, or, to
     the knowledge of such counsel, any order, judgment, or decree material to
     and binding on the Company or to which any of its operations, businesses,
     properties, or assets are subject;

                (H) to such counsel's knowledge, except as identified in the
     Offering Memorandum or this Agency Agreement, there are no claims, actions,
     suits, investigations or proceedings before or by any arbitrator, court,
     governmental authority or instrumentality pending or, to such counsel's
     knowledge, threatened against or affecting the Company or involving the
     properties of the Company which might materially and adversely affect the
     business, properties or financial condition of the Company or which if
     determined adverse to the Company could reasonably be expected to
     materially adversely affect the transactions or other acts contemplated by
     this Agency Agreement or the validity or enforceability of this Agency
     Agreement, except as set forth in or contemplated by the Offering Documents
     or in Schedule 3(b)(v)(F); and

                (I) such counsel has participated in conferences with officers
     and other representatives of the Company, representatives of the
     independent public accountants for the Company and your representatives at
     which the contents of the Offering Memorandum and the Offering Documents
     and related matters were discussed and, although such counsel is not
     passing upon and do not assume any responsibility for the accuracy,
     completeness or fairness of the statements contained in the Offering
     Memorandum and the other Offering Documents (except as described in
     paragraphs D and F above), such counsel advises the Placement Agent that,
     on the basis of the

                                       12
<PAGE>

     foregoing (relying as to materiality to a large extent upon the opinions of
     officers and other representatives of the Company), no facts have come to
     such counsel's attention which lead us to believe that the Offering
     Memorandum and other Offering Documents as of their respective dates
     contained an untrue statement of a material fact or omitted to state a
     material fact required to be stated therein or necessary to make the
     statements therein, in the light of the circumstances under which they were
     made, not misleading (it being understood such counsel has not been
     requested to and does not make any comment with respect to the financial
     statements and other financial or statistical data included in the Offering
     Memorandum).

        (vi) Officers' Certificate. The Placement Agent shall receive a
     certificate of the Company, signed on its behalf by the Chief Executive
     Officer and Chief Financial Officer thereof, that (i) the representations
     and warranties contained in Section 2 hereof are true and accurate at such
     closing with the same effect as though expressly made at such closing and
     (ii) the Company has complied with its covenants and agreements set forth
     herein.

        (vii) Designation of Preferred. The Series D Designation shall have been
     accepted for filing by the Secretary of State of the State of Delaware.

        (viii) Fund Escrow Agreement. The Placement Agent shall receive a copy
     of a duly executed escrow agreement in the form previously delivered to the
     Placement Agent regarding the deposit of funds pending the closing(s) of
     the Offering with a bank or trust company acceptable to the Placement Agent
     (the "Fund Escrow Agreement").

        (ix) Lock-Up Agreements. The Placement Agent shall receive agreements
     from each executive officer and director of the Company (collectively, the
     "Existing Stockholders") to the effect that such person shall not sell,
     assign or transfer any of their Common Stock, preferred stock or other
     securities of the Company for a period of 15 months from the Initial
     Preferred Closing; provided however, the foregoing lock-up period for such
     individuals may be extended for the same period (up to an additional twelve
     months) of extension agreed to by the Placement Agent and Subscribers as
     described below. The Placement Agent shall receive agreements from each
     Subscriber to the effect that such Subscriber shall not sell, assign or
     transfer any of their Preferred Units or shares of Common Stock underlying
     such units for a period of up to 12 months from the Initial Preferred
     Closing; provided however, the foregoing lock-up period for such
     Subscribers may be extended by agreement between the Placement Agent and
     the Subscribers for an additional 12 months. If Subscribers who own 25% or
     more of the Preferred Units issued in the Offering are released from any
     such lock-up agreement by the Placement Agent, the Existing Stockholders
     shall be released effective on the 90th day thereafter. The Placement Agent
     covenants that it will not sell, assign or transfer any of its Bridge
     Warrants, Agency Warrants, or their underlying shares of stock unless the
     lock-up period applicable to the Subscribers has expired or all Subscribers
     have been released form their lock-up agreements; provided, however,
     without limiting the foregoing, the Placement Agent may sell, assign or
     transfer such securities to its affiliates and employees provided they
     agree to be bound by the terms of this Section 3(b)(ix).

        (x) Upon the Initial Preferred Closing, the Board of Directors will
     consist of seven directors which shall include three members designated by
     the Company (who

                                       13
<PAGE>

     shall be reasonably acceptable to the Placement Agent), two members
     designated by the Placement Agent and two members designated by the
     Subscribers. At least three of the members of the Board collectively
     designated by the Placement Agent and the Subscribers shall be "independent
     directors" (as such term is defined in Rule 4200 of the Nasdaq Stock
     Market). The Placement Agent shall receive the irrevocable proxies
     described in Section 4(h) hereof. In the event that any of the parties does
     not exercise its respective right to designate a member or members of the
     Board, then the failure to do so shall not constitute a waiver of such
     right and such party may then appoint any person to be an observer who
     shall be entitled to attend and observe meetings of the Board and any
     committees thereof (an receive notices, communications and other
     information provided in connection with such meetings). The parties
     acknowledge that the initial designees of the Company shall be Dr. C.
     Everett Koop, Donald Hacket and John Zaccaro.

        (xi) O&D Insurance. The Company shall have in place and full force and
     effect at least $5,000,000 of officers and directors liability insurance.

        (xii) No Adverse Changes. There shall not have occurred, at any time
     prior to the applicable closing (i) a general suspension of, or a general
     limitation on prices for, trading in securities on the New York Stock
     Exchange or the Nasdaq -Amex Stock Exchange or in the over-the-counter
     market; (ii) any outbreak of major hostilities or other national or
     international calamity; (iii) any banking moratorium declared by Federal or
     New York authorities; (iv) any material adverse change in the business,
     properties, assets, results of operations, or financial condition of the
     Company which materially impairs the investment quality of the Preferred
     Units; or (v) any material adverse change in the market for securities in
     general or in political, financial, or economic conditions which, in the
     Placement Agent's reasonable judgment, makes it inadvisable to proceed with
     the Offering.

        (xiii) Employment Agreement. The Company and each of Donald Hackett and
     Louis Scalpati shall have amended his existing employment to provide for a
     one year extension or entered into a new employment agreement upon terms
     reasonably acceptable to the Placement Agent.

        (xiv) License Agreement. That certain second amended and restated name
     and likeness agreement, dated June 5, 2000, between the Company and Dr. C.
     Everett Koop shall have been amended on terms satisfactory to the Placement
     Agent, it being understood that the form of amendment presented to the
     Placement Agent is satisfactory except that the change in control provision
     in Attachment A shall only apply in the event of a sale to tobacco, alcohol
     or weapons interests.

     (c) Blue Sky. Counsel to the Placement Agent will prepare and file the
necessary documents so that offers and sales of the securities to be offered in
the Offering may be made in certain jurisdictions in the United States. It is
understood that such filings may be based on or rely upon: (i) the
representations of each Subscriber set forth in the Subscription Agreement
delivered by such Subscriber; (ii) the representations, warranties and
agreements of the Company set forth in Section 2 of this Agency Agreement; and
(iii) the representations of the Company set forth in the certificate to be
delivered at each Preferred Closing pursuant to paragraph (vi) of Section 3(b).

                                       14
<PAGE>

     (d) Placement Fee and Expenses.

        (i) Bridge Financing. Simultaneously with the payment for and delivery
     of the Bridge Notes on the date hereof, the Company shall pay or execute
     and deliver to the Placement Agent (A) the $25,000 payment which, together
     with the $25,000 non-refundable payment previously paid to the Placement
     Agent, shall be credited against the reimbursable expenses as set forth in
     subsection (ii)(B) below and (B) the Bridge Warrants.

        (ii) Offering. Simultaneously with payment for and delivery of the
     Preferred Units at each Preferred Closing, the Company shall: (A) pay to
     the Placement Agent a cash fee equal to 7% of the gross proceeds of the
     Preferred Units sold; (B) reimburse the Placement Agent for accountable
     expenses, which expenses, inclusive of the Placement Agent's expenses in
     Section 4(b), shall not exceed $150,000 in the aggregate; and (C) issue to
     the Placement Agent, or its designees, warrants, in the form attached as
     Appendix C, to purchase a number of Preferred Units of equal to 10% of the
     number of Preferred Units sold in the Offering (the "Agency Warrants"). The
     Company shall also pay all expenses in connection with the qualification of
     the Preferred Shares or Preferred Units under the blue sky laws of the
     states which the Placement Agent shall designate, including legal fees and
     filing fees not to exceed $5,000.

        (iii) Interest. In the event that for any reason the Company shall fail
     to pay to the Placement Agent all or any portion of the fees payable
     hereunder when due, interest shall accrue and be payable on the unpaid cash
     balance due hereunder from the date when first due through and including
     the date when actually collected by the Placement Agent, at a rate equal to
     four percent above the prime rate of Citibank, N.A., in New York, New York,
     computed on a daily basis and adjusted as announced from time to time.

     (e) Bring-Down Opinions and Certificates. If there is more than one
Preferred Closing, then at each such Closing there shall be delivered to the
Placement Agent updated opinions and certificates as described in (v) and (vi)
of Section 3(b) above, respectively.

4.  Covenants of the Company.

     (a) Use of Proceeds. The net proceeds of the Offering will be used by the
Company substantially as set forth in the Offering Memorandum. Except as set
forth on Schedule 4(a), the Company shall not use any of the proceeds from the
Offering to repay any indebtedness of the Company (other than trade payables as
they become due) outstanding on the date hereof, including but not limited to
indebtedness to any current executive officers, directors or principal
stockholders of the Company.

     (b) Expenses of Offering and Other Payments. The Company shall be
responsible for, and shall bear all expenses directly incurred in connection
with, the Offering including, but not limited to, (i) legal fees of the
Company's counsel relating to the costs of preparing the Offering Documents and
all amendments, supplements and exhibits thereto and preparing this Agency
Agreement and delivering all Preferred Units and Bridge Securities; and (ii) the
blue sky fees, filing fees and the fees and disbursements of Placement Agent's
counsel in connection with the blue sky matters as limited above (the "Company
Expenses").

                                       15
<PAGE>

     Prior to the Initial Preferred Closing, if the Company decides not to
proceed with the Offering for any reason (other than Placement Agent's failure
to close on the Offering prior to the Preferred Termination Date or upon mutual
agreement with the Placement Agent not to proceed with the Offering) or if the
Placement Agent decides not to proceed with the Offering because of a material
breach by the Company of its representations, warranties, or covenants in this
Agency Agreement or as a result of material adverse changes in the affairs of
the Company, the Company will be obligated to pay the Placement Agent a
financial advisory fee of $500,000 payable at the Placement Agent's sole
discretion in either cash or in shares of the Common Stock based on the closing
bid price on the date thereof (which fee the Company agrees is a fair measure of
the compensation to be received by the Placement Agent in respect of, among
other things its advice, time and effort in respect of the Offering), and to
reimburse the Placement Agent for the Placement Agent Expenses as set forth
above within ten business days of the occurrence or any such event. The
Placement Agent shall have no liability to the Company for any reason should the
Placement Agent choose not to proceed with the Offering contemplated hereby.

     (c) Notification. The Company shall notify the Placement Agent immediately,
and in writing, (i) when any event shall have occurred during the period
commencing on the date hereof and ending on the later of the Final Closing or
the Preferred Termination Date as a result of which the Offering Documents would
include any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein
not misleading, and (ii) of the receipt of any notification with respect to the
modification, rescission, withdrawal or suspension of the qualification or
registration of the Preferred Units, or of any exemption from such registration
or qualification, in any jurisdiction. The Company will use its reasonable best
efforts to prevent the issuance of any such modification, rescission, withdrawal
or suspension and, if any such modification, rescission, withdrawal or
suspension is issued and the Placement Agent so requests, to obtain the lifting
thereof as promptly as possible.

     (d) Blue Sky. The Company will use its reasonable best efforts to qualify
or register the securities to be offered in the Placements for offering and sale
under, or establish an exemption from such qualification or registration under,
the blue sky laws of such jurisdictions in the United States as the Placement
Agent may reasonably request; provided however, that the Company will not be
obligated to register as a foreign corporation or qualify as a dealer in
securities in any jurisdiction in which it is not so qualified. The Company will
not consummate any sale of securities pursuant to the Placements in any
jurisdiction in which it is not so qualified or in any manner in which such sale
may not be lawfully made.

     (e) Form D Filing. The Company shall: (i) file with the SEC five copies of
a Notice of Sales of Securities on Form D with respect to the sale of the
Preferred Units within the time period required; (ii) file promptly such
amendments to such Notices on Form D as shall become necessary; and (iii) comply
with any filing requirement imposed by the laws of any state or jurisdiction in
which offers and sales are made. Upon request, the Company shall furnish the
Placement Agent with copies of all such filings.

     (f) Press Releases, Etc. The Company shall provide two business days prior
written notice of any proposed press release or other communication, or any
press conference

                                       16
<PAGE>

with respect to any material development concerning the Company, its financial
condition, results of operations, business, properties, assets, or liabilities;
provided however, the Company may issue any press release without such prior
notice if in the reasonable opinion of counsel to the Company issuance before
such notice can be provided is required for compliance with any governmental
agency or exchange on which the Company's securities are listed. Furthermore,
the Company shall not at any time include information with respect to the use of
the Placement Agent's name in any press release, advertisement or on any website
maintained by the Company without the prior written consent of the Placement
Agent.

     (g) Restrictions on Issuances of Securities. During the period commencing
on the date hereof and ending on the later of (i) the Final Closing or (ii) the
Preferred Termination Date, provided the Placement Agent shall not have breached
any material covenant, representation or warranty contained in this Agency
Agreement and the Placement Agent is actively conducting the Offering, the
Company will not, without the prior written consent of the Placement Agent,
issue additional shares of Common Stock, other than pursuant to the exercise of
options, warrants or rights outstanding on the date hereof, or grant any
warrants, options or other securities of the Company. If the Minimum Offering is
sold, the Company agrees that it will not, without approval of the Placement
Agent issue additional shares of Common Stock, other than pursuant to the
exercise of options or warrants outstanding on the date hereof, or grant any
warrants, options or other securities of the Company.

     (h) Board Designees; Irrevocable Proxy. In the event the Minimum Offering
is completed, the Company agrees that as long as there shall be at least 400,000
D Preferred Shares outstanding (the "Board Representation Period"), it shall use
reasonable efforts to cause the Board to have the composition set forth in
Section 3(b)(x) hereof, and the number of directors comprising the Board shall
not increase without the consent of the Placement Agent's Board designees. It
shall be a condition of the appointment of any director by the Placement Agent
or any of the investors in the D Preferred Shares that such person agree in
advance to resign from the Board of Directors at the expiration of the Board
Representation Period notwithstanding that the term of office for such director
has not yet expired. The class of these directorships will be determined at the
time of appointment. The Placement Agent shall receive an irrevocable proxy
(revocable upon transfer of the voting stock to which it relates) from each of
the executive officers and directors of the Company granting the Placement Agent
a proxy to vote their shares for the election of directors solely for the
purpose of enforcing the Placement Agent's rights described in this Section
4(h). Any director designated by the Placement Agent may be replaced at any
time. In addition, in the event that any director designated by the Placement
Agent resigns or for any reason no longer serves as a director, then the
Placement Agent shall designate a replacement for such director. The Placement
Agent Board designees described in this Section 4(h) who are employees of
Commonwealth or its affiliates shall abstain from voting on or vote against
matters authorizing the issuance of securities that would trigger the anti-
dilution provisions contained in section 2.4 of the Series D Designation, which
procedure will be conformed into the by-laws of the Company and will apply to
the appointment of any director by any other investor in securities of the
Company that contain anti-dilution provisions.

                                       17
<PAGE>

     (i) Independent Auditors. During the three-year period following the
Initial Preferred Closing, the Company will not switch auditors, other than to a
"Big Five" accounting firm, without the approval of a majority of the
independent members of the Board of Directors.

     (j) Quarterly Communications. Within 45 days after the end of each fiscal
quarter, the Company shall (i) send to the Placement Agent (x) a letter setting
forth the results of operations for the fiscal quarter and management's analysis
thereof (which delivery obligation shall be satisfied by timely filing with the
SEC the applicable quarterly report on Form 10-Q) and (y) a schedule of all
securities issuances by the Company, including the issuances of shares pursuant
to the cashless exercise provisions of any options or warrants, and (ii) present
an update on the affairs of the Company at the offices of the Placement Agent
for the Subscribers and employees of the Placement Agent. In addition, within 90
days after the end of each fiscal year, the Company shall send to the
Subscribers a stockholders letter in form and substance reasonably satisfactory
to the Placement Agent setting forth the results of operations for the fiscal
year and management's analysis thereof (which delivery obligation shall be
satisfied by timely filing with the SEC the applicable annual report on
Form 10-K).

     (k) Transmittal Letters. Within five days after each closing of the
Offering, the Placement Agent shall receive copies of all letters from the
Company to the Subscribers transmitting the securities sold in the Offering and
shall receive a letter from the Company confirming transmittal of the securities
to the Subsidiaries.

     (l) Committees. The Company will not create any committees of its Board of
Directors that are not composed of a majority of the independent members of the
Board of Directors unless it has received the approval of a majority of the
independent members of the Board of Directors to do so.

     (m) Transfer Agent. The Company shall provide a transfer agent and
registrar in respect of its capital stock, which transfer agent and registrar
shall be reasonably acceptable to the Placement Agent.

5.  Indemnification.

     (a) The Company agrees to indemnify and hold harmless the Placement Agent
and each selected dealer, if any, and their respective stockholders, directors,
officers, agents and controlling persons (an "Indemnified Party") against any
and all loss, liability, claim, damage and expense whatsoever (and all actions
in respect thereof), and to reimburse the Placement Agent for reasonable legal
fees and related expenses as incurred (including, but not limited to the costs
of investigating, preparing or defending any such action or claim whether or not
in connection with litigation in which the Placement Agent is a party and the
costs of giving testimony or furnishing documents in response to a subpoena or
otherwise), caused by or arising out of (i) any untrue statement or alleged
untrue statement of a material fact contained in the Offering Documents or the
omission or alleged omission therefrom of a material fact necessary in order to
make the statements therein, in light of the circumstances under which they were
made, not misleading (provided, however, that the Company shall not be liable in
any such case to the extent that any such loss, liability, claim, damage or
expense arises out of or is based upon any untrue statement of a material fact
or alleged untrue statement or a material fact provided by

                                       18
<PAGE>

the Placement Agent in writing to the Company specifically for use in the
Offering Documents), any violation by the Company of the federal securities laws
or the securities laws of any states, or otherwise arising out of the Placement
Agent's engagement hereunder, except in respect of any matters as to which the
Placement Agent shall have been adjudicated to have acted with gross negligence,
or (iii) any breach by the Company of any of its representations, warranties or
covenants contained in this Agency Agreement.

     (b) Promptly after receipt by an Indemnified Party under this Section of
notice of the commencement of any action, the indemnified party will, if a claim
in respect thereof is to be made against the Company under this Section, notify
in writing the Company of the commencement thereof; but the omission so to
notify the Company will not relieve it from any liability which it may have to
the Indemnified Party otherwise than under this Section except to the extent the
defense of the claim is prejudiced. In case any such action is brought against
an Indemnified Party, and it notifies the Company of the commencement thereof,
the Company will be entitled to participate in, and, to the extent that it may
wish, jointly with any other indemnifying party similarly notified, to assume
the defense thereof, subject to the provisions herein stated, with counsel
reasonably satisfactory to the Indemnified Party, and after notice from the
Company to the Indemnified Party of its election so to assume the defense
thereof, the Company will not be liable to the Indemnified Party under this
Section for any legal or other expenses subsequently incurred by the Indemnified
Party in connection with the defense thereof other than reasonable costs of
investigation (provided the Company has been advised in writing that such
investigation is being undertaken). The Indemnified Party shall have the right
to employ separate counsel in any such action and to participate in the defense
thereof, but the fees and expenses of such counsel shall not be at the expense
of the Company if the Company has assumed the defense of the action with counsel
reasonably satisfactory to the Indemnified Party; provided that the fees and
expenses of such counsel shall be at the expense of the Company if (i) the
employment of such counsel has been specifically authorized in writing by the
Company (which it shall have no obligation to do) or (ii) the named parties to
any such action (including any impleaded parties) include both the Indemnified
Party or Parties and the Company and, in the reasonable judgment of counsel for
the Indemnified Party, it is advisable for the Indemnified Party or Parties to
be represented by separate counsel due to material conflict of interest (in
which case the Company shall not have the right to assume the defense of such
action on behalf of an Indemnified Party or Parties), it being understood,
however, that the Company shall not, in connection with any one such action or
separate but substantially similar or related actions in the same jurisdiction
arising out of the same general allegations or circumstances, be liable for the
reasonable fees and expenses of more than one separate firm of attorneys for all
the Indemnified Parties. No settlement by an Indemnified Party of any action
against an Indemnified Party shall be made without the Company's consent which
shall not be unreasonably withheld. No settlement of any action against an
Indemnified Party by the Company shall be made unless such an Indemnified Party
is fully and completely released in connection therewith.

6.  Contribution.

     To provide for just and equitable contribution, if (i) an Indemnified
Party makes a claim for indemnification pursuant to Section 5 but it is found in
a final judicial determination, not subject to further appeal, that such
indemnification may not be enforced in such case, even

                                       19
<PAGE>

though this Agency Agreement expressly provides for indemnification in such
case, or (ii) any indemnified or indemnifying party seeks contribution under the
1933 Act, the 1934 Act, or otherwise, then the Company (including for this
purpose any contribution made by or on behalf of any officer, director, employee
or agent for the Company, or any controlling person of the Company), on the one
hand, and the Placement Agent and any Selected Dealers (including for this
purpose any contribution by or on behalf of an indemnified party), on the other
hand, shall contribute to the losses, liabilities, claims, damages, and expenses
whatsoever to which any of them may be subject, in such proportions as are
appropriate to reflect the relative benefits received by the Company, on the one
hand, and the Placement Agent and the Selected Dealers, on the other hand;
provided, however, that if applicable law does not permit such allocation, then
other relevant equitable considerations such as the relative fault of the
Company and the Placement Agent and the Selected Dealers in connection with the
facts which resulted in such losses, liabilities, claims, damages, and expenses
shall also be considered. In no case shall the Placement Agent or a Selected
Dealer be responsible for a portion of the contribution obligation in excess of
the compensation received by it or the Selected Dealer Agreement, as the case
may be. No person guilty of a fraudulent misrepresentation shall be entitled to
contribution from any person who is not guilty of such fraudulent
misrepresentation. For purposes of this Section 6, each person, if any, who
controls the Placement Agent or a Selected Dealer within the meaning of Section
15 of the 1933 Act or Section 20(a) of the 1934 Act and each officer, director,
shareholder, employee and agent of the Placement Agent or a Selected Dealer,
shall have the same rights to contribution as the Placement Agent or the
Selected Dealer, and each person, if any who controls the Company within the
meaning of Section 15 of the 1933 Act or Section 20(a) of the 1934 Act and each
officer, director, employee and agent of the Company, shall have the same rights
to contribution as the Company, subject in each case to the provisions of this
Section 6. Anything in this Section 6 to the contrary notwithstanding, no party
shall be liable for contribution with respect to the settlement of any claim or
action effected without its written consent. This Section 6 is intended to
supersede any right to contribution under the 1933 Act, the 1934 Act, or
otherwise.

7.  Miscellaneous.

     (a) Survival. Any termination of the Offering without consummation thereof
shall be without obligation on the part of any party except that the
indemnification provided in Section 5 hereof and the contribution provided in
Section 6 hereof shall survive any termination and shall survive the Final
Closing for a period of three years.

     (b) Representations, Warranties and Covenants to Survive Delivery. The
respective representations, warranties, indemnities, agreements, covenants and
other statements as of the date hereof shall survive execution of this Agency
Agreement and delivery of the Preferred Units and the termination of this Agency
Agreement for a period of three years after such respective event.

     (c) No Other Beneficiaries. This Agency Agreement is intended for the sole
and exclusive benefit of the parties hereto and their respective successors and
controlling persons, and no other person, firm or corporation shall have any
third-party beneficiary or other rights hereunder.

                                       20
<PAGE>

     (d) Governing Law; Resolution of Disputes. This Agency Agreement shall be
governed by and construed in accordance with the law of the State of New York
without regard to conflict of law provisions. The Placement Agent and the
Company will attempt to settle any claim or controversy arising out of this
Agency Agreement through consultation and negotiation in good faith and a spirit
of mutual cooperation. Should such attempts fail, then the dispute will be
mediated by a mutually acceptable mediator to be chosen by the Placement Agent
and the Company within 15 days after written notice from either party demanding
mediation. Neither party may unreasonably withhold consent to the selection of a
mediator, and the parties will share the costs of the mediation equally. Any
dispute which the parties cannot resolve through negotiation or mediation within
six months of the date of the initial demand for it by one of the parties may
then be submitted to the courts for resolution. The use of mediation will not be
construed under the doctrine of latches, waiver or estoppel to affect adversely
the rights of either party. Nothing in this paragraph will prevent either party
from resorting to judicial proceedings if (a) good faith efforts to resolve the
dispute under these procedures have been unsuccessful or (b) interim relief from
a court is necessary to prevent serious and irreparable injury.

     (e) Counterparts. This Agency Agreement may be signed in counterparts with
the same effect as if both parties had signed one and the same instrument.

     (f) Notices. Any communications specifically required hereunder to be in
writing, if sent to the Placement Agent, will be sent by overnight courier
providing a receipt of delivery or by certified or registered mail to it at
Commonwealth Associates, 830 Third Avenue, New York, New York 10022, Att: Carl
Kleidman, with a copy to Paul, Hastings, Janofsky & Walker LLP, 75 East 55th
Street, New York, New York 10022, Att: Michael L. Zuppone, and if sent to the
Company, will be sent by overnight courier providing a receipt of delivery or by
certified or registered mail to it at 7000 N. Mopac, Suite 400, Austin, TX
78731, Att: Chief Executive Officer, with a copy to Latham & Watkins, 135
Commonwealth Drive, Menlo Park, California 94025-3656, Attention: Tony Richmond.

     (g) Entire Agreement. This Agency Agreement constitutes the entire
agreement of the parties with respect to the matters herein referred and
supersedes all prior agreements and understandings, written and oral, between
the parties with respect to the subject matter hereof including, but not limited
to, that certain engagement letter agreement, dated June 5, 2000, between the
Company and Commonwealth. Neither this Agency Agreement nor any term hereof may
be changed, waived or terminated orally, except by an instrument in writing
signed by the party against which enforcement of the change, waiver or
termination is sought.

     If you find the foregoing is in accordance with our understanding, kindly
sign and return to us a counterpart hereof, whereupon this instrument along with
all counterparts will become a binding agreement between us.

                                       21
<PAGE>

                              Very truly yours,

                              drkoop.com, Inc.

                              By:  /s/ Donald Hackett
                                   ------------------
                                   Name:   Donald Hackett
                                   Title:    CEO

Agreed:

COMMONWEALTH ASSOCIATES, L.P.

     By:  Commonwealth Associates Management Company, Inc.,
          its general partner

     By:  /s/ Joseph P. Wynne
          -------------------
          Name: Joseph P. Wynne
          Title: CFO

                                       22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]